out strategies for pain management could improve this PCS values and therefore reduce the need for TKR. Furthermore, this study also highlights the two main types of OA etiology: mechanical and inflammatory. It suggests that inflammation is mostly responsible for OA progression in patients with low BMI, and plays a strong role in women pathology. Finally, specific treatments targeting central pain sensitization could also improve the management of the pathology in women.

References:

Acknowledgments: MRCIN Funds are acknowledged (HOLOA-DPII2016-80283-C2-1/2-R)
Disclosed Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.5586

FRIO427 EULAR RECOMMENDATIONS FOR INTRA-ARTICULAR TREATMENTS FOR ARTHROPATHIES

Background: Intra-articular therapies (IAT) are widely used in clinical practice to treat patients with rheumatic and musculoskeletal diseases (RMDs). Many factors influence their efficacy and safety. There is a wide variation in the way IATs are delivered by health professionals. In an attempt to standardise these procedures, evidence-based recommendations are the right way forward.

Objectives: To establish evidence-based recommendations to guide health professionals using IAT in adult patients with peripheral arthropathies.

Methods: At a first face-to-face meeting, the results of an overview of systematic reviews were presented to the multidisciplinary task force of members from 8 countries. The aims, scope and outline of the task force were also established at this meeting. Thirty-two clinical questions ranked for priority (relevance for practice plus feasibility) drove the systematic reviews performed by two fellows. In addition, two surveys addressed to physicians, health professionals and patients throughout Europe were agreed to acquire more background information.

Inclusion criteria: Patients over 50 years of age with knee and/or hip osteoarthritis (OA). Patients with peripheral arthropathies (psoriatic arthritis, rheumatoid arthritis, etc.) were also included.

Exclusion criteria: Patients under 50 years of age, patients with inflammatory arthritis, patients with severe comorbidities or severe mobility impairments who are likely to require hospitalisation for their OA.

Results: Recommendations focus on practical aspects for daily practice to guide health professionals before, during and after IAT in adult patients with peripheral arthropathies. Five overarching principles were established, together with 11 recommendations that address the following issues: (1) patient information; (2) procedure and setting; (3) accuracy issues; (4) routine and special antiseptic care; (5) efficacy and safety of repeated joint injections; (6) the usage of local anaesthetics; and (7) aftercare. The document includes the supporting evidence and results from the surveys, level of evidence and agreement.

Conclusion: We have developed the first evidence and expert opinion based recommendations to guide health professionals using IAT.

Acknowledgments: EULAR Taskforce grant CL019

Disclosure of Interests: Jacquesonne Uson Jager: None declared, Esperanza Naredo: None declared, Sebastian C Rodriguez-Garcia Speakers bureau: Novartis Farmaceutica, S.A., Merck Sharp & Dohme España, S.A., Sanofi Aventis, UCB Pharma, Raul Castellanos-Moreira: None declared, Terence O’Neill: None declared, Hernant Pandit Grant/research support from: Glaxo Smith Kline (GSK) for work on Diclofenac Gel, Speakers bureau: Bristol Myers Squibb for teaching their use on hip and knee replacement, Michael Doherty Grant/research support from: AstraZeneca funded the Nottingham Sons of Gout study, Consultant: of Advisory boards on gout for Gruenthal and Mailickrodt, Mikael Boesen Consultant of: AbbVie, AstraZeneca, Eli Lilly, ESAOTE, Glenmark, Novartis, Pfizer, UCB, Paid instructor for: IAG, Image Analysis Group, AbbVie, Eli Lilly, AstraZeneca, esaote, Glenmark, Novartis, Pfizer, UCB (scientific advisor), Speakers bureau: Eli Lilly, Esasote, Novartis, Pfizer, UCB, Ingrid Möller: None declared, Valentina Vardanyan: None declared, Jenny de la Torre-Aboki: None declared, Lene Terslev: None declared, Francis Berenbaum Grant/research support from: TRB Chemedia (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lily, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Maria Antonietta D’Agostino Consultant of: AbbVie, BMS, Novartis, and Roche, Speakers bureau: AbbVie, BMS, Novartis, and Roche, Willim Uwe Kempen: None declared, Elena Nikihourou: None declared, IRENE Pissilidou: None declared, Loreto Carmona Grant/research support from: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie, Span, S.L.U., and Laboratorios Gepharma, SA.

DOI: 10.1136/annrheumdis-2020-eular.5813

FRIO428 RESULTS FROM A CROSS-SECTIONAL, OBSERVATIONAL STUDY TO ASSESS INADEQUATE PAIN MANAGEMENT IN PATIENTS WITH KNEE AND/OR HIP OSTEOARTHRITIS IN CHINA

Background: Osteoarthritis (OA) of the knee and hip is a leading cause of disability worldwide, particularly due to the primary symptoms of pain in the weight-bearing joints. There is limited data that characterizes patients who experience moderate to severe pain despite analgesic treatment in China.

Objectives: This study estimates the real-world prevalence of inadequate pain relief (IPR) among patients with knee and/or hip OA who have been prescribed analgesic therapy and characterizes this patient population. The study was conducted in China, the Philippines, Thailand, Russia, and Mexico. This abstract presents results from China.

Methods: This is a multinational, multi-site, cross-sectional, observational study. Physicians managing patients with OA were recruited and asked to enroll patients over 50 years of age with knee and/or hip OA who had been prescribed topical and/or oral pain medication for at least 30 days prior to study visit. Patients were included in the study if they reported daily pain, functional impairment and health-related quality of life (HRQoL) using patient reported outcome (PRO) instruments. Physicians abstracted data from patient charts. IPR was defined as an average pain score of >4/10 on Brief Pain Inventory Question #5 (average pain). Statistical tests including chi-square for categorical variables and Mann-Whitney Wilcoxon test for continuous variables were conducted to assess differences in demographic and clinical characteristics as well as PROs between patients with and without IPR. Multivariate logistic regression analysis was conducted to assess the relationship between IPR and PROs.

Results: 571 patients treated at 10 hospital centers in China were enrolled. 73% were female, the mean (SD) age was 62 (8.32) years. The number of years with OA ranged from less than one year to over 37 years, suggesting a broad sample of patients. Most patients were impacted by knee OA only (90%). Almost half (43%) of the patients reporting knee pain. IPR was more likely to be older, have greater prevalence of obesity, have more comorbidities, and had longer disease duration. The majority (98%) of patients were receiving nonsteroidal anti-inflammatory drugs (NSAIDs), followed by chondroprotective...
medications (23%). However, more patients with IPR mentioned being dissatisfied with treatment (38% vs. 21%). After adjusting for covariates, patients with IPR reported worse HRQOL, more functional limitations, and reduced work productivity compared to patients without IPR.

Conclusion: IPR is highly prevalent among individuals with knee and/or hip OA in China and is associated with decreased HRQOL and work productivity, impaired function, and treatment dissatisfaction. Developing awareness among healthcare professionals about the presence and potential impact of IPR is important for the ultimate improvement of OA patient management.


DOI: 10.1136/annrheumdis-2020-eular.5813

Disclosure of Interests: None declared


DOI: 10.1136/annrheumdis-2020-eular.5813

Disclosure of Interests: None declared

Disclosure of Interests: None declared